Scientific Publications Filter by Program All Programs AB002 AB023A2 AB011A3 AB054 AB062 Thrombopoietin inhibition abrogates JAK2V617F clonal expansion in a murine model of myeloproliferative neoplasm Seanoon et al. 67th ASH Annual Meeting Abstract December 6, 2025 Evaluating reversal strategies for long-acting factor XI antibodies: NovoSeven®, FEIBA®, Kcentra®, novel FXI mutants, and an anti-idiotypic antibody Wallisch et al. 67th ASH Annual Meeting Abstract December 6, 2025 Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial Verbout et al. Communications Medicine July 26, 2024 Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow Keeling et al. Journal of Thrombosis and Haemostasis May 22, 2024 Activation of coagulation FXI promotes endothelial inflammation and amplifies platelet activation in a nonhuman primate model of hyperlipidemia Kohs et al. Research and Practice in Thrombosis and Haemostasis January 1, 2024 Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation Meyer et al. ASAIO December 1, 2023 Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial Pfeffer et al. Arteriosclerosis, Thrombosis, and Vascular Biology November 16, 2023 Endogenous Protein C Activation with AB002 Improves Outcomes in a Rat Model of Acute Ischemic Stroke Verbout et al. Blood November 2, 2023 Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice Kohs et al. Metabolic Brain Disease June 21, 2023 Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease Sparkenbaugh et al. Blood April 13, 2023 First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men Nowotny et al. Journal of Thrombosis and Haemostasis July 20, 2022 Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial Lorentz et al. Blood December 2, 2021 Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus Silasi et al. Blood July 15, 2021 Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice Ngo et al. Journal of Thrombosis and Haemostasis April 19, 2021 Crystalizing our view of the contact system Tucker, EI Blood October 1, 2020 Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets Barrett et al. Journal of Thrombosis and Haemostasis July 18, 2020 The protein C activator AB002 rapidly interrupts thrombus development in baboons. Tucker et al. Blood February 27, 2020 Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates Wallisch et al. Research and Practice in Thrombosis and Haemostasis February 11, 2020 Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice Shirai et al. Blood Advances October 22, 2019 AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa Chan et al. Arteriosclerosis, Thrombosis, and Vascular Biology March 27, 2019 A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain Ivanov et al. Blood March 7, 2019 Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death Silasi et al. Blood Advances February 26, 2019 Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial Lorentz et al. Arteriosclerosis, Thrombosis, and Vascular Biology January 31, 2019 Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis Verbout et al. Metabolic Brain Disease May 9, 2014 Factor XII inhibition reduces thrombus formation in a primate thrombosis model Matafanov et al. Blood March 13, 2014 Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis Luo et al. Infection and Immunity December 22, 2012 Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke Berny-Lang et al. Stroke October 1, 2012 Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis Vicente et al. Thrombosis Research October 1, 2012 Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis Tucker et al. Blood May 17, 2012 The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A Flick et al. Blood June 9, 2011 A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo Cheng et al. Blood November 11, 2010 Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates Tucker et al. Science Translational Medicine June 23, 2010 Feedback controversy stops here Meijers, Joost Blood July 9, 2009 Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI Tucker et al. Blood January 22, 2009 Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist Berny et al. Arteriosclerosis, Thrombosis, and Vascular Biologu October 25, 2007 Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates Gruber et al. Blood January 16, 2007 The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo Gruber et al. Journal of Biological Chemistry August 2, 2002
